Daniel S. Levine

Hematologist oncologist Marina Kremyanskaya and PV patient advocate Nona Baker discuss the chronic rare blood cancer, how it reshapes everyday life for patients, and the promise of new therapies in development. @GlobalGenes #RARECast globalgenes.org/raredaily/from…

@BenZeskind @Immuneering discusses how the company is using its informatics-driven dosing regimen to re-engineer targeted cancer therapy so it extends survival, delays resistance, and is better tolerated.

@BenZeskind @Immuneering discusses how the company is using its informatics-driven dosing regimen to re-engineer targeted cancer therapy so it extends survival, delays resistance, and is better tolerated.

@BenZeskind @Immuneering discusses how the company is using its informatics-driven dosing regimen to re-engineer targeted cancer therapy so it extends survival, delays resistance, and is better tolerated. thebioreport.podbean.com/e/outsmarting-…

@hopeforpdcd CEO Frances Pimentel and parent board member Kim Higbee share how PDCD families are reacting to the FDA’s refusal of an experimental therapy—and why endpoints in a study miss the lived patient benefits. @globalgenes #RARECast globalgenes.org/raredaily/6523…

@hopeforpdcd CEO Frances Pimentel and parent board member Kim Higbee share how PDCD families are reacting to the FDA’s refusal of an experimental therapy—and why endpoints in a study miss the lived patient benefits. @globalgenes #RARECast globalgenes.org/raredaily/6523…

@GoogleCloud @ShwetaManiar on why life sci cos must treat AI as a strategic upgrade to de-risk science rather than a tool for improving efficiency—and how messy data, culture change, and multi-agent systems speed the path from discovery to patients. youtube.com/watch?v=zZrZaC…

@googlecloud @ShwetaManiar discusses why life sci cos must treat AI as a strategic upgrade to de-risk science rather than a tool for improving efficiency—and how messy data, culture change, and multi-agent systems speed the path from discovery to patients. youtube.com/watch?v=zZrZaC…

Richard Freed @RheumaGen_ , discusses role of HLA genes in autoimmune diseases, how the company’s gene-editing therapies work, and its lead program in rheumatoid arthritis. thebioreport.podbean.com/e/editing-away…

NYT: Dr. Vinay Prasad, a polarizing figure at the Food and Drug Administration who oversaw vaccines, is leaving the agency at the end of April, according to a Health and Human Services spokesman. nytimes.com/live/2026/03/0…

Rachel McMinn @NeurogeneInc , about Rett syndrome, the company’s technology for controlling gene expression, and the encouraging data they’ve seen so far. @GlobalGenes #RARECast globalgenes.org/raredaily/reop…

Fangning Zhang @McKinsey's Shanghai office explains why Asia is becoming a biopharma innovation powerhouse, how it could lower drug development costs, and why treating Asia as optional risks missing the next wave of global R&D. Podcast: thebioreport.podbean.com/e/why-asia-is-…

Here's what you may have missed in February from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. linkedin.com/pulse/hitting-…

@tigerminer , lead author of @wef0orum paper, discusses how smarter collection, sharing and analysis of rare disease data could unlock multi-trillion dollar gains in human health—and what it’ll take to rally global stakeholders. @GlobalGenes #RARECast globalgenes.org/raredaily/a-da…

.@scotchmcclure @MaxwellBiosci , explains why AI is becoming the engine of modern drug development—speeding discovery, filtering noise in massive datasets, and taking on more of the scientific process under clear vision and guardrails. youtube.com/watch?v=A9lE-0…

Leukemia survivor and @Columbia hematologist-oncologist @TheDoctorIsVin is reimagining blood cancer care—moving from blunt chemo to precision strategies that rewire malignant cells, epigenetic programs, and their ecosystems. thebioreport.podbean.com/e/reprogrammin…

Rajani Aatre of Michigan Medicine discusses the importance of cascade genetic testing, ethical tensions around its use, and the question of how to share life changing genetic information with relatives. @GlobalGenes #RARECast globalgenes.org/raredaily/when…

.@TernsPharma 's CEO Amy Burroughs discusses a strategic shift from metabolic disease to focus on the company's experimental therapy for chronic myeloid leukemia and how she is charting a clear path toward a broader oncology future. thebioreport.podbean.com/e/a-strategic-…

.@CartesianTX Carsten Brunn discusses how the company’s RNA‑engineered CAR T cells target the root cause of autoimmune diseases, data from its study in myasthenia gravis, and the potential to expand indications. @GlobalGenes #RARECast globalgenes.org/raredaily/chan…

Drew McCormick, head of data and analytics for @EVERSANAcompany , sits down with Nagaraja Srivatsan to trace the company’s AI journey from classic predictive modeling in its data and analytics business to an enterprise-wide strategy. youtube.com/watch?v=eKuWnd…